The mechanism of the hypoglycemic
Sulfonylureas have two modes of hypoglycemic action; one is insulinotropic and the other extrapancreatic.
However, the mechanism of the hypoglycemic action of sulfonylureas during long-term treatment has not been fully elucidated. Some studies have suggested that an increase in insulin release, which is generally accepted as a mechanism of short-term hypoglycemic action, is not necessarily observed in diabetics with good control for years. Reaven and Dray (1967) and other investigators (Duckworth, Solomon and Kitabchi, 1972; Barnes et al., 1974 ) have reported that the insulin level in peripheral venous blood during chronic treatment was lower than shortly after the initiation of sulfonylurea treatment. These findings have given rise to the hypothesis that chronic hypoglycemic effect is chiefly due to extrapancreatic action.
However, there are some objections to the interpretation of the reports describing how chronic treatment with sulfonylureas reduces insulin secretion. Since the diabetic state is not necessarily stationary, the release of insulin may be diminished as time goes on, Subjects: Twenty-four patients (sixteen males and eight females) with noninsulin-dependent diabetes mellitus, who had been treated with sulfonylureas for 1.5 to 19yr in the out-patient clinic, were studied. Clinical data on these patients are summarized in Table 1 . They ranged in age from 41 to 75yr, and duration of diabetes was from 2 to 19yr. Only three patients exceeded their ideal body weight (IBW) by 20% or more, which was calculated as follows;
Fourteen patients had been taking glibenclamide, six acetohexamide, two tolbutamide, and one each chlorpropamide and glymidine sodium.
Procedure:
The first 3h oral glucose tolerance test (OGTT) was carried out after an overnight fast when sulfonylureas were withheld on the day of examination.
The treatment was then discontinued for a month and the second OGTT was done. During the period without medication their diet and physical activities were kept constant, and the patients were periodically given medical observation. None of them developed ketoacidosis.
Informed consent was obtained from all patients before participating in this clinical study.
Blood samples for plasma glucose and serum immunoreactive insulin (IRI) were drawn from an antecubital vein at fasting, 30, 60, 90, 120 and 180min after a 100g glucose load. Plasma glucose was measured by the method of Hoffman (1937). Serum IRI was assayed by the solid phase immunoassay method (Wide and Porath, 1966) using Phadebas kits from Pharmacia.
All samples for IRI obtained from each individual were processed in the same assay to eliminate interassay variations.
The glucose area or IRI area under plasma glucose or the serum IRI response curve was calculated as follows; 0.5 where an is the value at "n" min after glucose load. Student's paired t-test was used to compare mean values before and after the discontinuation of sulfonylurea treatment in each group, and an unpaired t-test was used to compare them before discontinuation in two groups. 
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